Assessment Answers-Pharmaceutical Benefits Scheme: PHAR9120

Assessment Answers-Pharmaceutical Benefits Scheme: PHAR9120

1
Running head-SUMMARY
Clinical Development of New Medicines
Student name:
Student ID:
2
Running head-SUMMARY
Prices list on the PBS (Pharmaceu …

Preview text

1
Running head-SUMMARY
Clinical Development of New Medicines
Student name:
Student ID:
2
Running head-SUMMARY
Prices list on the PBS (Pharmaceutical Benefits Scheme) for infliximab and
adalimumab, according to API (Australian Pharmaceutical Industries) .
Infliximab acts as the tumor necrosis factor inhibitor that is used in managing autoimmune
conditions. The drug obtained approval from FDA in the year 1998. Adalimumab is another
appropriate alternative drug based on the human monoclonal antibody, which is being utilised
on the patients. The drugs are generally used to provide revolutionised care to patients with
Crohn’s disease (Persico et al., 2020) .However, Humira got the approval in the year 2002.
Both the medications are effective in managing the diseases. However, the alternative
medication Humira possesses acure against more diseases in comparison to infliximab. The
diseases cured by infliximab are rheumatoid arthritis, psoriatic arthritis, and ankylosing
spondylitis. Adding to the disease cure, Humira can cure juvenile idiopathic arthritis also.
Further, a person with any immune disease will rarely encounter all five diseases. Hence,
generally, people will find the infliximab drug more cost effective to purchase than the
Humira drug.
Pricing package for infliximab in Australia
The pricing list for infliximab according to Pharmaceutical Benefits Scheme in Australian
Pharmaceutical Industries is 42.50, which covers the volume of 100 mg injection (Australian
Government Department of Health, n.d. b). However, the Pharmaceutical Benefits Scheme
for an other medication, named adalimumab (Humira), is 2.5 times more expensive than
infliximab, which has arange of 42.50 $40 mg.
The pricing list for infliximab in Australia is satisfactory and lesser than its alternative
medication, Humira. Hence, the infliximab drug will be appreciated more by the patients.
However, increasing the pricing list of infliximab from 42.50 $per 100 mg to 42 $per 80 mg
will also be effective and satisfactory to purchase. Even after increasing the price or reducing
3
Running head-SUMMARY
the drug volume, infliximab will be highly recommended as it possesses approximately half
of the cost of Humira. Infliximab costs 42.50 $ will be per 80 mg, whereas Humira costs
42.50 $will be per 40 mg (Australian Government Department of Health, n.d. a).
4
Running head-SUMMARY
References
Persico A, Kwon S, Wegrzyn E, & Fudin J., (2020). Tumor Necrosis Factor (TNF) Inhibitors: A
Clinical Primer. Pract Pain Manag, 20(4).
https://www.practicalpainmanagement.com/treatments/pharmacological/tumor-necrosis-factor-
tnf-inhibitors-clinical-primer
Australian Government Department of Health, (n.d. a). Adalimumab. Pharmaceutical
Benefits Scheme (PBS). https://www.pbs.gov.au/medicine/item/5282B-5284D-8965W-
8966X-9099X-9100Y-9101B-9102C-9103D-9104E-9190Q-9191R-9426D-9428F-9663N-
9680L
Australian Government Department of Health, (n.d. b). Infliximab. Pharmaceutical Benefits
Scheme (PBS). https://www.pbs.gov.au/medicine/item/4284L-5753T-5754W-5755X-5756Y-
5757B-5758C-6397Q-6448J-6496X-9612X-9613Y-9617E-9654D-9674E

Order Now

QUALITY: 100% ORIGINAL PAPER – NO PLAGIARISM – CUSTOM PAPER